Trial intelligence / Profile preview

CAIV-T vs TIV for Influenza in Older Adults

NCT00192413Phase 3Completed

Sponsor
MedImmune
Start
Mar 2002
Primary completion
Nov 2002
Modality
Vaccines & Immunotherapeutics
Countries
1
01

Overview

Phase 3, randomised, open-label trial of live attenuated influenza vaccine in influenza (2 arms), sponsored by MedImmune. Primary endpoint: First episode of culture-confirmed influenza-illness caused by community-acquired subtypes antigenically similar to those contained in the vaccine. Started Mar 2002; status: completed.

02

Drugs

live attenuated influenza vaccine
03

Conditions

influenza

Beyond the preview

Go deeper on NCT00192413.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00192413.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call